Gotistobart

DRUG2 trials

Sponsors

OncoC4, Inc.

Conditions

Advanced Solid TumorNon Small Cell Lung Cancer

Phase 3

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Active, not recruitingNCT05671510

OncoC4, Inc.Non Small Cell Lung Cancer

Start: 2023-06-28End: 2028-08-31Target: 630Updated: 2026-08-13

Gotistobart Long Term Extension (LTE) Study

Enrolling by invitationNCT07659379

OncoC4, Inc.Advanced Solid Tumor

Start: 2026-07-28End: 2037-01-01Target: 20Updated: 2026-08-24

Related Papers

Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial

Nature Medicine2026-03-27

Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy.

Journal of Clinical Oncology2023-06-016 citations

PRESERVE-003: Phase 3, two-stage, randomized study of ONC-392 versus docetaxel in metastatic non-small cell lung cancers that progressed on PD-1/PD-L1 inhibitors.

Journal of Clinical Oncology2023-06-012 citations